Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
